Annals of Pediatric Cardiology
About us | Current Issue | Archives | Ahead of Print | Instructions | Submission | Subscribe | Advertise | Contact | Login 
  Instructions 
  Search 
  My preferences 

 


This article has been cited by
1Question 2 Is levosimendan better than milrinone in preventing post operative low cardiac output syndrome and improving cardiac function in children with congenital heart disease?
Sridhurga Udayasankar
Archives of Disease in Childhood.2017;102(6)590
[DOI]
2CARDIAC-Exploring the Pleiotropic Effects of Levosimendan Impact on Systemic Inflammatory Parameters and Molecular Salvage Path-ways by Modulation of Cytokine Levels and Tissue Apoptosis Rate
Udo Boeken,Moritz Benjamin Immohr,Alexander Jenke,Annika Jahn,Laura Dohrn,Markus Kornfeld,Antonio Pinto,Artur Lichtenberg,Payam Akhyari
Journal of Heart and cardiology.2017;3(1)1
[DOI]
3CARDIAC-Exploring the Pleiotropic Effects of Levosimendan Impact on Systemic Inflammatory Parameters and Molecular Salvage Path-ways by Modulation of Cytokine Levels and Tissue Apoptosis Rate
Frank A. Maffei,Jennifer E. L. Diep,Arno L. Zaritsky
Journal of Heart and cardiology.2021;3(1)559
[DOI]
4First Experience With Levosimendan Therapy After Correction of Congenital Heart Disease
Raffaele Giordano,Massimiliano Cantinotti,Vito Antonio Mannacio,Gaetano Palma
Journal of Cardiothoracic and Vascular Anesthesia.2017;31(1)e19
[DOI]